Patents by Inventor Marston Manthorpe
Marston Manthorpe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120141577Abstract: The disclosure relates to a linear expression cassette (LEC) as a nucleic acid based vector for producing a gene product of interest. Methods of preparing a disclosed LEC, as well as methods for its use to express a gene product in a subject, are also described. An LEC may be used in an animal or human subject to produce a therapeutic and/or immune response in the subject, such as an immunized state.Type: ApplicationFiled: December 3, 2007Publication date: June 7, 2012Applicant: Vical IncorporatedInventors: Marston Manthorpe, Adrian Vilalta, Alain Rolland
-
Patent number: 8080642Abstract: The present invention is directed to raising a detectable immune response in a vertebrate by administering in vivo, into a tissue of the vertebrate, at least one polynucleotide comprising one or more regions of nucleic acid encoding a SARS-CoV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to raising a detectable immune response in a vertebrate by administering, in vivo, into a tissue of the vertebrate, at least one SARS-CoV protein or a fragment, a variant, or derivative thereof. The SARS-CoV protein can be, for example, in purified form. The polynucleotide is incorporated into the cells of the vertebrate in vivo, and an immunologically effective amount of an immunogenic epitope of a SARS-CoV polypeptide, fragment, variant, or derivative thereof is produced in vivo. The SARS-CoV protein is also administered in an immunologically effective amount.Type: GrantFiled: May 12, 2004Date of Patent: December 20, 2011Assignee: Vical IncorporatedInventors: Adrian Vilalta, Thomas G. Evans, Melanie W. Quong, Marston Manthorpe
-
Publication number: 20110081686Abstract: A reactor and methods of use are disclosed for amplification of an amplicon. The reactor includes a housing having a fluid path with a fluid inlet and a fluid outlet and one or more reaction chambers suitable for housing the amplicon. The reaction chambers are positioned within the housing in thermal communication with a fluid flowing in the fluid path to heat and/or cool the reaction chambers and the inside of the reaction chambers are coated with or are a plastic material. A variable temperature fluid source is in fluid communication with the fluid inlet and the fluid source is configured to provide fluid at temperatures suitable for amplification, including a denature temperature, an anneal temperature, and an extension temperature. A controller is coupled to the variable temperature fluid source to control a fluid temperature within the fluid path by controlling the variable temperature fluid source.Type: ApplicationFiled: September 30, 2010Publication date: April 7, 2011Applicant: Vical IncorporatedInventors: C. Marston MANTHORPE, Mark E. MINICK, Edward M. DOMANICO
-
Patent number: 7470675Abstract: The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon ? and one or more cationic compounds. The present invention also provides methods of treating cancer in a mammal, comprising administering into a tissue of the mammal a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding a cytokine. In addition, the present invention also relates to the methodology for selective transfection of malignant cells with polynucleotides expressing therapeutic or prophylactic molecules in intra-cavity tumor bearing mammals. More specifically, the present invention provides a methodology for the suppression of an intra-cavity dissemination of malignant cells, such as intraperitoneal dissemination.Type: GrantFiled: February 23, 2007Date of Patent: December 30, 2008Assignee: Vical IncorporatedInventors: Holly Horton, Suezanne Parker, Marston Manthorpe, Philip L. Felgner, Jukka Hartikka
-
Publication number: 20070225243Abstract: The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon ? and one or more cationic compounds. The present invention also provides methods of treating cancer in a mammal, comprising administering into a tissue of the mammal a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding a cytokine. In addition, the present invention also relates to the methodology for selective transfection of malignant cells with polynucleotides expressing therapeutic or prophylactic molecules in intra-cavity tumor bearing mammals. More specifically, the present invention provides a methodology for the suppression of an intra-cavity dissemination of malignant cells, such as intraperitoneal dissemination.Type: ApplicationFiled: February 23, 2007Publication date: September 27, 2007Inventors: Holly Horton, Suezanne Parker, Marston Manthorpe, Philip Felgner, Jukka Hartikka
-
Patent number: 7268120Abstract: The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon ? and one or more cationic compounds. The present invention also provides methods of treating cancer in a mammal, comprising administering into a muscle of the mammal a non-infectious, non-integrating DNA polynucleotide construct comprising a polynucleotide encoding a cytokine. In addition, the present invention also relates to the methodology for selective transfection of malignant cells with polynucleotides expressing therapeutic or prophylactic molecules in intra-cavity tumor bearing mammals. More specifically, the present invention provides a methodology for the suppression of an intra-cavity dissemination of malignant cells, such as intraperitoneal dissemination.Type: GrantFiled: April 21, 2000Date of Patent: September 11, 2007Assignee: Vical IncorporatedInventors: Holly Horton, Suezanne Parker, Marston Manthorpe, Philip L. Felgner, Jukka Hartikka
-
Publication number: 20070105193Abstract: The present invention is directed to raising a detectable immune response in a vertebrate by administering in vivo, into a tissue of the vertebrate, at least one polynucleotide comprising one or more regions of nucleic acid encoding a SARS-CoV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to raising a detectable immune response in a vertebrate by administering, in vivo, into a tissue of the vertebrate, at least one SARS-CoV protein or a fragment, a variant, or derivative thereof. The SARS-CoV protein can be, for example, in purified form. The polynucleotide is incorporated into the cells of the vertebrate in vivo, and an immunologically effective amount of an immunogenic epitope of a SARS-CoV polypeptide, fragment, variant, or derivative thereof is produced in vivo. The SARS-CoV protein is also administered in an immunologically effective amount.Type: ApplicationFiled: May 12, 2004Publication date: May 10, 2007Applicant: Vical IncorporatedInventors: Adrian Vilalta, Thomas Evans, Melanie Quong, Marston Manthorpe
-
Patent number: 6875748Abstract: The present invention relates to pharmaceutical compositions and methods to improve expression of exogenous polypeptides into vertebrate cells in vivo, utilizing delivery of polynucleotides encoding such polypeptides. More particularly, the present invention provides the use of salts, in particular sodium and potassium salts of phosphate, in aqueous solution, and auxiliary agents, in particular detergents and surfactants, in pharmaceutical compositions and methods useful for direct polynucleotide-based polypeptide delivery into the cells of vertebrates.Type: GrantFiled: April 23, 2001Date of Patent: April 5, 2005Assignee: Vical IncorporatedInventors: Marston Manthorpe, Jukka Hartikka, Loretta Sukhu, Jennifer Meek
-
Publication number: 20020019358Abstract: The present invention relates to pharmaceutical compositions and methods to improve expression of exogenous polypeptides into vertebrate cells in vivo, utilizing delivery of polynucleotides encoding such polypeptides. More particularly, the present invention provides the use of salts, in particular sodium and potassium salts of phosphate, in aqueous solution, and auxiliary agents, in particular detergents and surfactants, in pharmaceutical compositions and methods useful for direct polynucleotide-based polypeptide delivery into the cells of vertebrates.Type: ApplicationFiled: April 23, 2001Publication date: February 14, 2002Applicant: Vical IncorporatedInventors: Marston Manthorpe, Jukka Hartikka, Loretta Sukhu
-
Patent number: 5958875Abstract: This invention provides compounds displaying NGF agonist activity, wherein the compounds comprise a multimer of a sequence of amino acid residues or biologically functional equivalents thereof, the sequence being substantially homologous to residues 29-38 of NGF, residues 43-47 of NGF or residues 92-97 of NGF. Preferably, the multimer is a cyclic dimer wherein the monomeric amino acid sequences are linked to each other by disulfide bridges. This invention also provides methods and compositions for the treatment of disorders involving NGF-responsive cells, by administering an effective amount of the multimeric NGF agonists of this invention to an individual suffering from such disorder.Type: GrantFiled: March 29, 1996Date of Patent: September 28, 1999Assignee: The Regents of the University of CaliforniaInventors: Frank M. Longo, Marston Manthorpe